We use cookies for a better user experience. Read our Privacy Policy

I Agree

Biosimilars Market

Biosimilars Market (Product: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Biosimilars Market Outlook 2031

  • The global biosimilars market was valued at US$ 20.4 Bn in 2021
  • The global market is expected to advance at a CAGR of 15.5% from 2022 to 2031
  • The global biosimilars market is anticipated to reach more than US$ 85 Bn by the end of 2031

Analysts’ Viewpoint on Biosimilars Market Scenario

Several pharmaceutical companies across the world are engaged in the development of biosimilars. The global biosimilars market has the potential to grow at a rapid pace. Large numbers of biological drugs are likely to go off patent. Therefore, lower healthcare costs and regulatory structure changes by governments are expected to drive the market during the forecast period. Usage of monoclonal antibodies in the treatment of COVID-19 has also renewed interest in the biosimilars market. However, implementation of strict policies and market entry barriers for new players are likely to restrain the global market. Manufacturers are increasing their research capabilities to develop improved immunotherapy drugs. These drugs hold the potential to reduce the incidence of side effects in cancer patients. Rise in availability of insurance coverage for biosimilars is also creating a positive impact on the market.

biosimilars market

Overview of Biosimilars Market

Biosimilar can be defined as a biologic medical product, which is considered very similar to an already-approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and the standards of pharmaceutical quality that apply to all biologic medicines.

Biosimilars are generic versions of biologics that have passed their patent expiration date. The global biosimilars market is expected to be driven by patent expiration of well-known biologics. Increase in approval and sales of biosimilars has led to a significant decline in sales of biologics that had a steady or growing demand.

The burden of chronic diseases has been rising across the globe. Increase in prevalence of chronic diseases can be largely ascribed to the aging population and changing lifestyle of the people. Diabetes, hypertension, stroke, respiratory diseases, oral diseases, obesity, arthritis, and cancer are some of the common chronic diseases. On the other hand, biosimilar monoclonal antibodies are being extensively used in the treatment of rheumatoid arthritis and cancer.

Approvals of biosimilars have been increasing globally owing to changing regulations and rise in pressure on healthcare systems to facilitate treatment for all patients. Biosimilars or copy biologics are being increasingly adopted by physicians, authorities, and patients, owing to the much-needed improvements in the access to therapeutically viable options for the treatment of various diseases. Companies are increasing the production of biosimilar medicines, oncology biosimilars, and Remicade biosimilars to broaden their revenue streams.

Request a sample to get extensive insights into the Biosimilars Market

High Prevalence of Chronic Diseases and Rise in Number of Cancer Patients to Boost Biosimilars Market

Rise in prevalence of chronic diseases is augmenting the global market. Biosimilar drugs are becoming increasingly popular across the world because of their cost-effectiveness. Increase in cancer patients and chronic disease cases; and growth in geriatric population are projected to fuel the demand for biosimilars during the forecast period.

Over half of the population of the U.S. is likely to suffer from at least one chronic disease during their lifetime. According to the WHO, chronic disease prevalence is expected to rise by 57% by 2020. Rapid population growth in emerging markets is expected to drive the prevalence of chronic diseases.

Cancer is the second leading cause of death globally, with over 70% of deaths occurring in low- and middle-income countries. The incidence of cancer increases with age, most likely due to the rise in risk of specific cancers as people get older. Growth in pipeline of biosimilar drugs for the treatment of chronic diseases is projected to propel the global biosimilars market in the next few years. ABRILADA, a biosimilar to Humira, was approved by the U.S. Food and Drug Administration (FDA) in November 2019 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

Changing Government Regulations to Augment Demand for Recombinant Non-glycosylated Protein Products

In terms of product, the recombinant non-glycosylated proteins segment held a relatively large market share in 2021. The segment has been split into insulin, granulocyte colony stimulating factor, recombinant human growth factor, and interferons.

Recombinant non-glycosylation involves the production of active substances in bacteria, which results in non-glycosylation, allowing the active substance to remain biologically active. Growth of the segment can be attributed to the rise in the prevalence of chronic diseases, which require recombinant non-glycosylated proteins biosimilars for treatment. Additionally, changing regulations and increase in focus of governments on the approval of biosimilars are anticipated to drive the recombinant non-glycosylated proteins segment during the forecast period.

Advancements in Biomedical Technology to Drive Oncology Treatments

Based on indication, the oncology segment held large revenue share of the global biosimilars market in 2021. Growth in prevalence of cancer and increase in the number of ongoing studies in the biosimilars filed across the world are likely to augment the segment during the forecast period.

Biologics are a broad category of products that include blood and blood components, vaccines, hormones, and allergens (anti-allergy medications). Monoclonal antibodies are important biologics; these are used to treat a range of diseases, including breast cancer, lymphoma, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease.

Advancements in biomedical technology have resulted in an increase in commercialization of biologics in the last few decades. This has improved cancer care. Cancer treatment is expensive; therefore, development of a biosimilar product with comparable clinical efficacy has led to lower healthcare costs and improved access to care. Hence, the oncology segment is expected to account for significant share of the market during the forecast period.

Regional Outlook of Global Biosimilars Market

Europe held more than 45% share of the global biosimilars market in 2021. It is projected to be a highly lucrative region of the global market, with high market attractiveness index, during the forecast period.

The biosimilars market in Europe is the largest in the world, accounting for roughly 60% of the global biosimilars market and growing steadily year after year. As of October 2019, 54 biosimilars of 15 originator biological medicines were approved for marketing in Europe. Countries in Europe provide valuable examples of different approaches to biosimilars policy, led by their large biosimilars markets and diverse healthcare systems.

Biosimilars sales reflect Europe's legislative and regulatory leadership in the market. The biosimilars markets in the region is more mature than that in the U.S. However, opportunities for biosimilars companies in Europe are limited due to lower overall spending on biologicals.

Europe has set the standard, approving more treatments than any other continent. Currently, biosimilars account for 10% of the total biologics market in the region, with a majority (7%) occurring in the past five years. The percentage is significantly higher in terms of volume, reflecting the steadily increasing level of revenue savings as a result of the rise in biosimilars competition and penetration. More than 60 biosimilars have been approved for use in the European Union (EU) to date, with several more being evaluated. Therefore, the biosimilars market in Europe is expected to grow at a significant pace during the forecast period.

Analysis of Key Players in Biosimilars Market

The global biosimilars market is consolidated, with a small number of leading players accounting for a relatively large share. Most of the companies are making significant investments in research & development activities. Diversification of product portfolio and mergers & acquisitions are important strategies adopted by key players in the global biosimilars market. Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion, Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex, Inc. are the prominent players operating in the global biosimilars market.

Request a custom report on Biosimilars Market

Key Developments in Global Biosimilars Market

  • In March 2022, Amneal Pharmaceuticals, Inc. announced that the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen, had been approved by the U.S. Food and Drug Administration (FDA). The product will be sold under the brand name RELEUKO.
  • In December 2021, Gedeon Richter, Hungary's largest drug maker, reached an agreement with Hikma Pharmaceuticals, a London-listed drug maker, to out-license biosimilars denosumab for commercialization in the U.S.
  • In July 2021, Biocon Ltd. (Biocon Biologics) received the FDA approval for the first interchangeable biosimilars SEMGLEE (insulin glargine-yfgn injection) for the treatment of diabetes in collaboration with Viatris, Inc.

Each of these players has been profiled in the biosimilars market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Biosimilars Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 20.4 Bn

Market Forecast Value in 2031

More than US$ 85 Bn

Growth Rate

(CAGR)

15.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value & Tons for Volume

Market Analysis

It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Recombinant Glycosylated Proteins
      • Monoclonal Antibodies
      • Erythropoietin
      • Others
    • Recombinant Non-glycosylated Proteins
      • Insulin
      • Granulocyte Colony Stimulating Factor
      • Recombinant Human Growth Factor
      • Interferons
    • Recombinant Peptides
  • Indication
    • Chronic Diseases
    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases
    • Blood Disorders
    • Growth Hormone Deficiency
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Pfizer, Inc.
  • Intas Pharmaceuticals Ltd.
  • Biocon
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH (A Novartis Division)
  • Celltrion Inc.
  • Amgen, Inc.
  • STADA Arzneimittel AG
  • Apotex Inc.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global biosimilars market in 2021?

The global biosimilars market was valued at US$ 20.4 Bn in 2021

How big will be the global biosimilars market in 2031?

The global biosimilars market is projected to reach more than US$ 85 Bn by 2031

What will be the CAGR of the global biosimilars market during the forecast period (2022–2031)?

The global biosimilars market is anticipated to expand at a CAGR of 15.5% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in approvals of biosimilars is expected to drive the global biosimilars market.

Which region will account for major share of the global biosimilars market during the forecast period?

Europe is expected to account for major share of the global biosimilars market during the forecast period.

Who are the prominent players in the global biosimilars market?

Prominent players in the global biosimilars market include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion, Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Biosimilars Market

5. Market Overview

    5.1. Definition

    5.2. Market Indicators

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunities

6. Market Outlook

    6.1. Global Biosimilars Market Analysis and Forecast, 2017–2031

    6.2. Global Biosimilars Market Outlook

    6.3. Entry Barriers to Biosimilars Market

    6.4. Factors Driving the Adoption of Biosimilars

    6.5. Pipeline Analysis

    6.6. Regulatory Scenario Assessment

    6.7. Key Industry Developments

7. Global Biosimilars Market Analysis and Forecast, by Product

    7.1. Introduction

    7.2. Biosimilars Market Value Forecast, by Product, 2017–2031

        7.2.1. Recombinant Glycosylated Proteins

            7.2.1.1. Monoclonal Antibodies

            7.2.1.2. Erythropoietin

            7.2.1.3. Others

        7.2.2. Recombinant Non-glycosylated Proteins

            7.2.2.1. Insulin

            7.2.2.2. Granulocyte Colony Stimulating Factor

            7.2.2.3. Recombinant Human Growth Factor

            7.2.2.4. Interferons

        7.2.3. Recombinant Peptides

    7.3. Market Attractiveness Analysis, by Product

8. Global Biosimilars Market Analysis and Forecast, by Indication

    8.1. Introduction

    8.2. Biosimilars Market Value Forecast, by Indication, 2017–2031

        8.2.1. Chronic Diseases

        8.2.2. Oncology

        8.2.3. Autoimmune Diseases

        8.2.4. Infectious Diseases

        8.2.5. Blood Disorders

        8.2.6. Growth Hormone Deficiency

        8.2.7. Others

    8.3. Market Attractiveness Analysis, by Material

9. Global Biosimilars Market Analysis and Forecast, by Region

    9.1. Regional Outlook

    9.2. Global Scenario

    9.3. Introduction

    9.4. Biosimilars Market Value Forecast, by Region

        9.4.1. North America

        9.4.2. Europe

        9.4.3. Asia Pacific

        9.4.4. Latin America

        9.4.5. Middle East & Africa

    9.5. Market Attractiveness Analysis, by Region

10. North America Biosimilars Market Analysis and Forecast

    10.1. Key Findings

    10.2. North America Biosimilars Market Value Forecast, by Product, 2017–2031

        10.2.1. Recombinant Glycosylated Proteins

            10.2.1.1. Monoclonal Antibodies

            10.2.1.2. Erythropoietin

            10.2.1.3. Others

        10.2.2. Recombinant Non-glycosylated Proteins

            10.2.2.1. Insulin

            10.2.2.2. Granulocyte Colony Stimulating Factor

            10.2.2.3. Recombinant Human Growth Factor

            10.2.2.4. Interferons

        10.2.3. Recombinant Peptides

    10.3. North America Biosimilars Market Value Forecast, by Indication, 2017–2031

        10.3.1. Chronic Diseases

        10.3.2. Oncology

        10.3.3. Autoimmune Diseases

        10.3.4. Infectious Diseases

        10.3.5. Blood Disorders

        10.3.6. Growth Hormone Deficiency

        10.3.7. Others

    10.4. North America Biosimilars Market Value Forecast, by Country, 2017–2031

        10.4.1. U.S.

        10.4.2. Canada

    10.5. North America Biosimilars Market Attractiveness Analysis

        10.5.1. By Product

        10.5.2. By Indication

        10.5.3. By Country

11. Europe Biosimilars Market Analysis and Forecast

    11.1. Key Findings

    11.2. Europe Biosimilars Market Value Forecast, by Product, 2017–2031

        11.2.1. Recombinant Glycosylated Proteins

            11.2.1.1. Monoclonal Antibodies

            11.2.1.2. Erythropoietin

            11.2.1.3. Others

        11.2.2. Recombinant Non-glycosylated Proteins

            11.2.2.1. Insulin

            11.2.2.2. Granulocyte Colony Stimulating Factor

            11.2.2.3. Recombinant Human Growth Factor

            11.2.2.4. Interferons

        11.2.3. Recombinant Peptides

    11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017–2031

        11.3.1. Chronic Diseases

        11.3.2. Oncology

        11.3.3. Autoimmune Diseases

        11.3.4. Infectious Diseases

        11.3.5. Blood Disorders

        11.3.6. Growth Hormone Deficiency

        11.3.7. Others

    11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

        11.4.1. U.K.

        11.4.2. Germany

        11.4.3. France

        11.4.4. Italy

        11.4.5. Spain

        11.4.6. Rest of Europe

    11.5. Europe Biosimilars Market Attractiveness Analysis

        11.5.1. By Product

        11.5.2. By Indication

        11.5.3. By Country/Sub-region

12. Asia Pacific Biosimilars Market Analysis and Forecast

    12.1. Key Findings

    12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017–2031

        12.2.1. Recombinant Glycosylated Proteins

            12.2.1.1. Monoclonal Antibodies

            12.2.1.2. Erythropoietin

            12.2.1.3. Others

        12.2.2. Recombinant Non-glycosylated Proteins

            12.2.2.1. Insulin

            12.2.2.2. Granulocyte Colony Stimulating Factor

            12.2.2.3. Recombinant Human Growth Factor

            12.2.2.4. Interferons

        12.2.3. Recombinant Peptides

    12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017–2031

        12.3.1. Chronic Diseases

        12.3.2. Oncology

        12.3.3. Autoimmune Diseases

        12.3.4. Infectious Diseases

        12.3.5. Blood Disorders

        12.3.6. Growth Hormone Deficiency

        12.3.7. Others

    12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

        12.4.1. China

        12.4.2. India

        12.4.3. Japan

        12.4.4. Australia & New Zealand

        12.4.5. Rest of Asia Pacific

    12.5. Asia Pacific Biosimilars Market Attractiveness Analysis

        12.5.1. By Product

        12.5.2. By Indication

        12.5.3. By Country/Sub-region

13. Latin America Biosimilars Market Analysis and Forecast

    13.1. Key Findings

    13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017–2031

        13.2.1. Recombinant Glycosylated Proteins

            13.2.1.1. Monoclonal Antibodies

            13.2.1.2. Erythropoietin

            13.2.1.3. Others

        13.2.2. Recombinant Non-glycosylated Proteins

            13.2.2.1. Insulin

            13.2.2.2. Granulocyte Colony Stimulating Factor

            13.2.2.3. Recombinant Human Growth Factor

            13.2.2.4. Interferons

        13.2.3. Recombinant Peptides

    13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017–2031

        13.3.1. Chronic Diseases

        13.3.2. Oncology

        13.3.3. Autoimmune Diseases

        13.3.4. Infectious Diseases

        13.3.5. Blood Disorders

        13.3.6. Growth Hormone Deficiency

        13.3.7. Others

    13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

        13.4.1. Brazil

        13.4.2. Mexico

        13.4.3. Rest of Latin America

    13.5. Latin America Biosimilars Market Attractiveness Analysis

        13.5.1. By Product

        13.5.2. By Indication

        13.5.3. By Country/Sub-region

14. Middle East & Africa Biosimilars Market Analysis and Forecast

    14.1. Key Findings

    14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017–2031

        14.2.1. Recombinant Glycosylated Proteins

            14.2.1.1. Monoclonal Antibodies

            14.2.1.2. Erythropoietin

            14.2.1.3. Others

        14.2.2. Recombinant Non-glycosylated Proteins

            14.2.2.1. Insulin

            14.2.2.2. Granulocyte Colony Stimulating Factor

            14.2.2.3. Recombinant Human Growth Factor

            14.2.2.4. Interferons

        14.2.3. Recombinant Peptides

    14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017–2031

        14.3.1. Chronic Diseases

        14.3.2. Oncology

        14.3.3. Autoimmune Diseases

        14.3.4. Infectious Diseases

        14.3.5. Blood Disorders

        14.3.6. Growth Hormone Deficiency

        14.3.7. Others

    14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

        14.4.1. GCC Countries

        14.4.2. South Africa

        14.4.3. Rest of Middle East & Africa

    14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis

        14.5.1. By Product

        14.5.2. By Indication

        14.5.3. By Country/Sub-region

15. Competition Landscape

    15.1. Competition Matrix

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. Pfizer, Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. Strategic Overview

            15.3.1.5. SWOT Analysis

        15.3.2. Intas Pharmaceuticals Ltd.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. Strategic Overview

            15.3.2.5. SWOT Analysis

        15.3.3. Biocon

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.4. Dr. Reddy’s Laboratories Ltd.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. Strategic Overview

            15.3.4.5. SWOT Analysis

        15.3.5. Teva Pharmaceutical Industries Ltd.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. Strategic Overview

            15.3.5.5. SWOT Analysis

        15.3.6. Sandoz International GmbH (A Novartis Division)

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. Strategic Overview

            15.3.6.5. SWOT Analysis

        15.3.7. Celltrion, Inc.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. Strategic Overview

            15.3.7.5. SWOT Analysis

        15.3.8. Amgen, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. Strategic Overview

            15.3.8.5. SWOT Analysis

        15.3.9. STADA Arzneimittel AG

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. Strategic Overview

            15.3.9.5. SWOT Analysis

        15.3.10. Apotex Inc. (Apobiologix)

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Financial Overview

            15.3.10.3. Product Portfolio

            15.3.10.4. Strategic Overview

            15.3.10.5. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis - Biosimilars

Table 02: Global Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 03: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 04: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 05: Global Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 06: Global Biosimilars Market Value (US$ Bn) Forecast, by Region, 2017–2031

Table 07: North America Biosimilars Market Value (US$ Bn) Forecast, by Country, 2017–2031

Table 08: North America Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031

Table 09: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 10: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 11: North America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 12: Europe Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Europe Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031

Table 14: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 15: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 16: Europe Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 17: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 19: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 20: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 21: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 22: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 23: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 24: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 25: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 26: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 27: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 28: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 29: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 30: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 31: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

List of Figures

Figure 01: Global Biosimilars Market Snapshot

Figure 02: Global Biosimilars Market Value (US$ Bn) by Region, 2021 and 2031

Figure 03: Global Biosimilars Market Value (US$ Bn) Forecast, 2021–2031

Figure 04: Global Biosimilars Market Value Share (%), by Product, 2021

Figure 05: Global Biosimilars Market Value Share (%), by Indication, 2021

Figure 06: Global Biosimilars Market Value Share (%), by Region, 2021

Figure 07: Entry Barriers to Biosimilars Market

Figure 08: Factors Driving the Adoption of Biosimilars

Figure 09: Biosimilar Approval Process - US

Figure 10: Data Requirements for Biosimilar Approval in Europe

Figure 11: Regulations for Biosimilar Approval in Japan

Figure 12: Regulations for Biosimilar Approval in India

Figure 13: Regulations for Biosimilar Approval in Brazil

Figure 14: Regulations for Biosimilar Approval in Saudi Arabia

Figure 15: Biosimilars Market - Key Product Launches

Figure 16: Global Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 17: Global Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 18: Global Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 19: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Figure 20: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Figure 21: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Peptides, 2017–2031

Figure 22: Global Biosimilars Market Value (US$ Bn) Forecast, by Monoclonal Antibodies, 2017–2031

Figure 23: Global Biosimilars Market Value (US$ Bn) Forecast, by Erythropoietin, 2017–2031

Figure 24: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017–2031

Figure 25: Global Biosimilars Market Value (US$ Bn) Forecast, by Insulin, 2017–2031

Figure 26: Global Biosimilars Market Value (US$ Bn) Forecast, by Granulocyte Colony Stimulating Factor, 2017–2031

Figure 27: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Human Growth Factor, 2017–2031

Figure 28: Global Biosimilars Market Value (US$ Bn) Forecast, by Interferons, 2017–2031

Figure 29: Global Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 30: Global Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 31: Global Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 32: Global Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 33: Global Biosimilars Market Value (US$ Bn) Forecast, by Chronic Diseases, 2017–2031

Figure 34: Global Biosimilars Market Value (US$ Bn) Forecast, by Oncology, 2017–2031

Figure 35: Global Biosimilars Market Value (US$ Bn) Forecast, by Autoimmune Diseases, 2017–2031

Figure 36: Global Biosimilars Market Value (US$ Bn) Forecast, by Infectious Diseases, 2017–2031

Figure 37: Global Biosimilars Market Value (US$ Bn) Forecast, by Blood Disorders, 2017–2031

Figure 38: Global Biosimilars Market Value (US$ Bn) Forecast, by Growth Hormone Deficiency, 2017–2031

Figure 39: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017–2031

Figure 40: Global Biosimilars Market Attractiveness Analysis, by Indication, 2021-2031

Figure 41: Global Biosimilars Market: Regional Outlook

Figure 42: Global Biosimilars Market Value Share Analysis, by Region, 2021 and 2031

Figure 43: Global Biosimilars Market Attractiveness Analysis, by Region, 2021-2031

Figure 44: North America Biosimilars Market Value (US$ Bn) Forecast, 2017–2031

Figure 45: North America Biosimilars Market Value Share Analysis, by Country, 2021 and 2031

Figure 46: North America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 47: North America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 48: North America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 49: North America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 50: North America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 51: North America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 52: North America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 53: North America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 54: North America Biosimilars Market Attractiveness Analysis, by Country, 2021 and 2031

Figure 55: Europe Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 56: Europe Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 57: Europe Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 58: Europe Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 59: Europe Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 60: Europe Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 61: Europe Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 62: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 63: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 64: Europe Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 65: Europe Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 66: Asia Pacific Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 67: Asia Pacific Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 68: Asia Pacific Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 69: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 70: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 71: Asia Pacific Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 72: Asia Pacific Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 73: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 74: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 75: Asia Pacific Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 76: Asia Pacific Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 77: Latin America Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 78: Latin America Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 79: Latin America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 80: Latin America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 81: Latin America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 82: Latin America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 83: Latin America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 84: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 85: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 86: Latin America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 87: Latin America Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 88: Middle East & Africa Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 89: Middle East & Africa Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 90: Middle East & Africa Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 91: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 92: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 93: Middle East & Africa Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 94: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 95: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 96: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 97: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 98: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 99: Global Biosimilars Market Share Analysis, by Company, 2018

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved